Zoetis Inc. $ZTS Holdings Cut by Raiffeisen Bank International AG

Key Points

• Raiffeisen Bank International AG cut its Zoetis stake by 78.8% in the second quarter, selling 194,968 shares and retaining 52,336 shares valued at approximately $3.8 million. Institutional investors collectively own 92.8% of Zoetis.
• Analysts have lowered their price targets, resulting in a consensus rating of “Hold” and an average target price of $107.43. Recent targets range from $80 to $94, with several firms maintaining neutral or equal-weight ratings.
• Zoetis shares opened at $75.70, near their 12-month low of $71.00 and well below the 12-month high of $155.15. The company modestly beat quarterly EPS expectations at $1.87, while revenue of $2.47 billion fell short of estimates and declined slightly year over year.

Raiffeisen Bank International AG reduced its stake in Zoetis Inc. (NYSE:ZTS - Free Report) by 78.8% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 52,336 shares of the company's stock after selling 194,968 shares during the period. Raiffeisen Bank International AG's holdings in Zoetis were worth $3,834,000 as of its most recent SEC filing.

Other institutional investors also recently made changes to their positions in the company. Brighton Jones LLC increased its position in Zoetis by 180.4% in the fourth quarter. Brighton Jones LLC now owns 4,629 shares of the company's stock worth $754,000 after buying an additional 2,978 shares during the period. Empowered Funds LLC grew its position in shares of Zoetis by 6.2% during the first quarter. Empowered Funds LLC now owns 11,293 shares of the company's stock worth $1,859,000 after acquiring an additional 657 shares during the last quarter. Intech Investment Management LLC increased its holdings in shares of Zoetis by 17.2% in the 1st quarter. Intech Investment Management LLC now owns 8,347 shares of the company's stock worth $1,374,000 after acquiring an additional 1,224 shares during the period. Sivia Capital Partners LLC lifted its position in Zoetis by 73.8% in the 2nd quarter. Sivia Capital Partners LLC now owns 3,348 shares of the company's stock valued at $522,000 after purchasing an additional 1,422 shares during the last quarter. Finally, Glenview Trust co boosted its stake in Zoetis by 11.8% during the 2nd quarter. Glenview Trust co now owns 4,780 shares of the company's stock valued at $745,000 after purchasing an additional 506 shares during the period. 92.80% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. TD Cowen dropped their price target on shares of Zoetis from $104.00 to $94.00 and set a "buy" rating on the stock in a research note on Tuesday, August 25th. Argus restated a "hold" rating on shares of Zoetis in a research report on Wednesday, May 27th. Barclays cut their target price on Zoetis from $136.00 to $85.00 and set an "equal weight" rating on the stock in a research note on Wednesday, July 1st. William Blair reiterated a "market perform" rating on shares of Zoetis in a research report on Thursday, August 6th. Finally, Piper Sandler decreased their price target on Zoetis from $90.00 to $80.00 and set a "neutral" rating for the company in a research note on Monday, August 10th. Eight analysts have rated the stock with a Buy rating, nine have given a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat.com, the company currently has an average rating of "Hold" and a consensus target price of $107.43.

Zoetis Trading Down 0.8%

Zoetis stock opened at $75.70 on Friday. The firm has a 50 day simple moving average of $75.53 and a 200-day simple moving average of $93.85. The company has a debt-to-equity ratio of 2.87, a current ratio of 3.08 and a quick ratio of 1.84. The stock has a market capitalization of $31.28 billion, a PE ratio of 12.47, a price-to-earnings-growth ratio of 1.78 and a beta of 0.73. Zoetis Inc. has a 12-month low of $71.00 and a 12-month high of $155.15.

Zoetis (NYSE:ZTS - Get Free Report) last announced its earnings results on Thursday, August 6th. The company reported $1.87 EPS for the quarter, topping the consensus estimate of $1.85 by $0.02. The firm had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.The firm's quarterly revenue was down .2% compared to the same quarter last year. During the same quarter in the previous year, the company earned $1.76 earnings per share. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. As a group, equities research analysts expect that Zoetis Inc. will post 6.2 EPS for the current fiscal year.

Zoetis Company Profile

Zoetis Inc NYSE: ZTS is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company's offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source